Metoclopramide
Is It Right for You?
A complete guide to Metoclopramide — what it treats, how it works, dosages, side effects, and when a clinician may prescribe it following an online consultation.
What Is Metoclopramide?
Metoclopramide is a centrally and peripherally acting antiemetic and prokinetic agent belonging to the substituted benzamide class. It exerts its effects through dopamine D2 receptor antagonism in the chemoreceptor trigger zone of the brain, combined with peripheral 5-HT4 receptor agonism that enhances upper gastrointestinal motility. This dual mechanism makes it useful for the short-term treatment of nausea and vomiting and for conditions associated with delayed gastric emptying.
Metoclopramide is available in the UK as oral tablets (10 mg), oral solution (5 mg/5 mL), and as a solution for injection (10 mg/2 mL) for intravenous or intramuscular administration. The choice of formulation depends on the clinical setting — oral therapy for ambulatory symptomatic relief, parenteral therapy for acute post-operative, post-chemotherapy, or migraine-associated nausea, and for patients unable to tolerate oral medication.
Following a 2013 European Medicines Agency review, the use of metoclopramide in the UK is restricted to short-term use only (maximum five days at the lowest effective dose) due to the risk of serious neurological side effects, including extrapyramidal reactions and tardive dyskinesia. It is no longer licensed for use in children under one year of age and is restricted to second-line use in young people aged 1–18.
Metoclopramide is a prescription-only medication in the UK. A licensed clinician must assess the underlying cause of nausea or vomiting, exclude contraindications, and confirm that short-term use is appropriate before prescribing.
What Conditions Is Metoclopramide Used For?
Metoclopramide is prescribed for short-term symptomatic management of:
Metoclopramide is licensed for the prevention and treatment of nausea and vomiting associated with cytotoxic chemotherapy, particularly in the delayed phase (24 hours or more after chemotherapy). It is generally used as an adjunct to more targeted antiemetics such as 5-HT3 antagonists (ondansetron, granisetron) and corticosteroids, rather than as monotherapy. Its prokinetic action on the upper gastrointestinal tract complements the antiemetic effect by reducing gastric stasis associated with chemotherapy.
Metoclopramide is used for the prevention and treatment of post-operative nausea and vomiting (PONV) in adults, typically given by intravenous or intramuscular injection in the immediate post-operative period. It is most often used as a second-line agent when first-line antiemetics (such as ondansetron or dexamethasone) have failed or are unsuitable, reflecting its less favourable neurological side-effect profile.
Metoclopramide is licensed as an adjunct to oral analgesia for the symptomatic treatment of acute migraine attacks. Its combined antiemetic and prokinetic actions reduce nausea and improve gastric emptying, which in turn accelerates the absorption of co-administered oral analgesics (such as paracetamol, aspirin, or NSAIDs). It is particularly useful in patients whose migraine attacks are accompanied by significant nausea or gastroparesis.
Metoclopramide is used short term (maximum five days) for nausea and vomiting from a variety of causes including post-radiotherapy nausea, drug-induced nausea (for example opioid-related), and acute gastroenteritis where vomiting is clinically problematic. Use should be limited to circumstances where a clear short-term clinical benefit is anticipated and other first-line antiemetics are unsuitable.
Metoclopramide is occasionally used to facilitate small bowel intubation and to accelerate gastric emptying in patients undergoing radiological examinations of the upper gastrointestinal tract, particularly small bowel studies. Its prokinetic effect on the upper gut shortens transit times and improves the quality of the examination.
Following a Europe-wide safety review, metoclopramide is now licensed only for short-term use (up to five days) at the lowest effective dose. This restriction reflects the risk of serious neurological side effects — including acute dystonic reactions, parkinsonism, and irreversible tardive dyskinesia — which increase significantly with prolonged use, higher doses, and in elderly or paediatric patients. It is not appropriate for chronic conditions such as gastroparesis or long-term reflux management in primary care.
How Does Metoclopramide Work?
Metoclopramide produces its antiemetic and prokinetic effects through a combination of central and peripheral mechanisms acting at multiple receptor sites:
Central dopamine D2 receptor antagonism (antiemetic action): Metoclopramide blocks dopamine D2 receptors in the chemoreceptor trigger zone (CTZ) of the area postrema in the medulla. The CTZ is a key relay station for nausea and vomiting signals, particularly those arising from circulating emetogenic substances such as opioids, chemotherapy agents, and metabolic disturbances. By antagonising D2 receptors here, metoclopramide reduces the transmission of emetic impulses to the vomiting centre, producing a centrally mediated antiemetic effect. This same dopamine antagonism in nigrostriatal pathways is responsible for its extrapyramidal side effects.
Peripheral 5-HT4 receptor agonism (prokinetic action): At therapeutic doses, metoclopramide stimulates serotonin 5-HT4 receptors on enteric cholinergic neurons in the upper gastrointestinal tract. This increases acetylcholine release at neuromuscular junctions in the smooth muscle of the oesophagus, stomach, and small intestine, enhancing peristalsis, increasing lower oesophageal sphincter tone, accelerating gastric emptying, and promoting forward transit through the duodenum and jejunum. Notably, it has minimal effect on colonic motility — distinguishing its mechanism from laxatives.
5-HT3 receptor antagonism (high-dose antiemetic action): At higher doses, metoclopramide also antagonises serotonin 5-HT3 receptors centrally in the CTZ and peripherally on vagal afferent nerves in the gut wall. This contributes to its efficacy in chemotherapy-induced nausea, where 5-HT3 pathway activation is a key emetogenic mechanism. However, the doses required for clinically significant 5-HT3 antagonism approach those associated with extrapyramidal side effects, which has limited the use of high-dose metoclopramide in modern oncology practice.
Dosages & Administration
The correct dose depends on the type and severity of infection, age, weight, and kidney function. Always follow your clinician's instructions. The table below is for general reference only.
Administration Tips
Take oral metoclopramide 30 minutes before meals and at bedtime where prescribed three times daily. Pre-meal dosing maximises the prokinetic effect on the stomach and small intestine, improving both antiemetic efficacy and the absorption of co-administered oral medication.
Swallow tablets whole with a glass of water. The oral solution (5 mg/5 mL) is available for patients who have difficulty swallowing tablets and can be measured precisely for paediatric or reduced-dose regimens.
Do not exceed five days of treatment. If your symptoms have not resolved by day five, contact your clinician for review rather than extending the course. Continued use significantly increases the risk of serious neurological side effects.
Do not exceed the maximum daily dose of 30 mg in adults (or 0.5 mg/kg/day in young people aged 1–18). Higher doses do not improve antiemetic efficacy and significantly increase the risk of extrapyramidal reactions.
Avoid alcohol and sedating medication during treatment. Metoclopramide commonly causes drowsiness, which can be compounded by other CNS depressants.
Stop treatment and seek urgent medical advice if you develop uncontrolled muscle movements, abnormal head, neck or eye posture, muscle stiffness, or restlessness — these are signs of acute dystonic reactions or tardive dyskinesia and require immediate review.
Side Effects of Metoclopramide
Most common side effects are mild and resolve on discontinuation. Serious neurological side effects — although uncommon — are the principal reason for the five-day duration limit and require immediate medical attention.
- Drowsiness, fatigue, or sedation — reported in approximately 10% of patients
- Restlessness, agitation, or akathisia (inner restlessness, compulsion to move)
- Headache
- Dizziness
- Diarrhoea
- Asthenia (weakness or loss of energy)
- Hypotension, particularly with rapid intravenous administration
- Menstrual irregularities and galactorrhoea (milky nipple discharge) with prolonged use, due to elevated prolactin
- Acute dystonic reactions — involuntary muscle spasms typically affecting the face, neck, or eyes (oculogyric crisis, torticollis, trismus); usually occur within the first 24–48 hours of treatment; higher risk in children and young adults; reversible with discontinuation and procyclidine
- Tardive dyskinesia — potentially irreversible involuntary movements of the face, tongue, and limbs; risk increases with prolonged use, higher doses, and in elderly patients (particularly women); the principal reason for the five-day duration limit
- Neuroleptic malignant syndrome (NMS) — rare but life-threatening; hyperthermia, muscle rigidity, autonomic instability, altered consciousness; requires immediate discontinuation and emergency care
- Parkinsonism — tremor, bradykinesia, rigidity; usually reversible on discontinuation but may persist; risk increases with age and dose
- Severe depression and suicidal ideation — rare but reported; monitor for new or worsening mood symptoms, particularly in those with a history of depression
- Cardiac conduction disturbances — bradycardia, AV block, and QT prolongation reported, particularly with intravenous use; cardiac monitoring advisable in high-risk patients
- Methaemoglobinaemia — rare; particularly in neonates and patients with G6PD deficiency
The single most clinically important safety issue with metoclopramide is the risk of tardive dyskinesia — a movement disorder characterised by involuntary repetitive movements of the face, tongue, and limbs that can be permanent. This risk rises sharply with use beyond five days, with higher daily doses, and with increasing patient age (particularly in women). The five-day maximum treatment duration is not a guideline but a strict licensing requirement designed to minimise this risk. Patients and prescribers must adhere to this limit without exception in primary care.
Drug Interactions
Metoclopramide interacts with a number of medications, most importantly those that act on the central dopaminergic and serotonergic systems. Always disclose all prescription medications, over-the-counter medicines, vitamins, and supplements to your clinician or pharmacist before starting metoclopramide.
Concurrent use of metoclopramide with antipsychotics (such as haloperidol, risperidone, olanzapine, aripiprazole) significantly increases the risk of extrapyramidal side effects — including acute dystonic reactions, parkinsonism, and tardive dyskinesia — because both drug classes block central dopamine D2 receptors. This combination should be avoided where possible.
Combining metoclopramide with SSRIs, SNRIs, MAOIs, tramadol, triptans, or other serotonergic drugs increases the theoretical risk of serotonin syndrome — a potentially serious reaction characterised by agitation, sweating, tremor, hyperthermia, and altered mental state. Although metoclopramide is primarily a dopamine antagonist, it has weak serotonergic activity. Caution is advised, particularly at higher doses or with multiple serotonergic agents.
Metoclopramide's dopamine antagonism directly opposes the action of dopamine agonists used in Parkinson's disease (such as levodopa, ropinirole, pramipexole, rotigotine), and can precipitate worsening of motor symptoms. Metoclopramide is contraindicated in patients with Parkinson's disease and should not be co-prescribed with dopaminergic antiparkinsonian therapy.
Metoclopramide enhances the central nervous system depressant effects of alcohol, opioids, benzodiazepines, sedating antihistamines, and hypnotics — increasing the risk of drowsiness, impaired concentration, and reduced ability to drive or operate machinery. Patients should avoid alcohol during treatment and use caution with other sedating medication.
Metoclopramide accelerates gastric emptying and can alter the rate — though not the overall extent — of absorption of other oral medications. Drugs primarily absorbed from the stomach (such as digoxin) may have reduced absorption, while drugs absorbed from the small intestine (such as ciclosporin and paracetamol) may be absorbed more rapidly. Clinical significance is usually modest, but plasma level monitoring may be advisable for narrow-therapeutic-index drugs.
Anticholinergic drugs (such as hyoscine, atropine, and tricyclic antidepressants) and opioid analgesics counteract the prokinetic effect of metoclopramide on the upper gastrointestinal tract by reducing acetylcholine release and slowing gut motility. Combining these classes may reduce the therapeutic benefit of metoclopramide for nausea and vomiting.
Important Warnings
Following a 2013 European Medicines Agency review, metoclopramide is licensed only for short-term use (maximum five days at the lowest effective dose) and at a maximum daily dose of 30 mg in adults. This restriction reflects the risk of serious and potentially irreversible neurological side effects — including tardive dyskinesia — which increase significantly with prolonged use, higher doses, and in elderly patients. Treatment must not be continued beyond five days under any circumstances without specialist review.
Metoclopramide can cause acute dystonic reactions (involuntary muscle spasms typically affecting the face, neck, or eyes) usually within the first 24–48 hours of treatment, and tardive dyskinesia (potentially permanent involuntary movements of the face, tongue, and limbs) with prolonged use. Risk is highest in children, young adults, the elderly, and at higher doses. Stop treatment and seek urgent medical advice if you develop uncontrolled movements, muscle stiffness, or unusual postures.
Metoclopramide is not licensed for use in children under one year of age and is restricted to second-line use only in young people aged 1–18 (such as for severe, persistent post-operative or chemotherapy-induced nausea where first-line agents have failed). Initiation in this age group should only be by a specialist clinician.
Metoclopramide is contraindicated in patients with confirmed or suspected gastrointestinal obstruction, perforation, or haemorrhage. By stimulating upper gut motility, it can worsen mechanical obstruction, precipitate perforation in compromised bowel wall, or aggravate bleeding. It is also contraindicated in patients with a history of pheochromocytoma due to the risk of hypertensive crisis.
Metoclopramide should not be used in patients with Parkinson's disease, a history of tardive dyskinesia or neuroleptic malignant syndrome, epilepsy, or those receiving other drugs likely to cause extrapyramidal reactions (including antipsychotics). It directly antagonises the dopaminergic therapy used in Parkinson's and can precipitate seizures in those with a history of epilepsy.
Metoclopramide can cause drowsiness, dizziness, and impaired alertness, particularly at initiation, in elderly patients, and when combined with alcohol or other sedating medication. You should not drive, operate machinery, or perform tasks requiring full alertness until you know how the medication affects you. Avoid alcohol during treatment.
Speak to a Clinician About Treatment
Getting advice no longer means sitting in a waiting room. Through The GP Service, you can consult with a licensed clinician in minutes — from home, on your lunch break, or wherever works for you. If treatment is clinically appropriate, your clinician can issue a prescription during the consultation. A consultation does not guarantee a prescription.
The treatment you need, when you need it.
Metoclopramide FAQs
Metoclopramide must not be used for longer than five days in a single treatment course. This restriction was introduced following a 2013 European safety review, which found that the risk of serious neurological side effects — including potentially irreversible tardive dyskinesia — increases significantly with longer use. If your nausea or vomiting persists beyond five days, contact your clinician for review and an alternative treatment plan rather than continuing metoclopramide.
The standard adult oral dose is 10 mg (one tablet) up to three times daily, taken before meals, with a maximum daily dose of 30 mg. Elderly patients and those with kidney or liver problems are usually started on a lower dose (5 mg three times daily). Always follow the specific dose your clinician has prescribed for you and do not exceed it.
Yes — metoclopramide commonly causes drowsiness, dizziness, and impaired concentration, particularly during the first few days of treatment. You should not drive, operate machinery, or carry out tasks requiring full alertness until you know how the medication affects you. The effect can be made worse by alcohol or other sedating medicines, which should also be avoided.
Stop taking metoclopramide and seek urgent medical advice if you develop uncontrolled muscle movements, abnormal posture of the head, neck or eyes, muscle stiffness, tremor, restlessness, or repetitive involuntary movements of the face or tongue. These can be signs of acute dystonic reactions or tardive dyskinesia, which are recognised but serious side effects of metoclopramide. The risk is higher in children, young adults, and with prolonged use.
Metoclopramide is generally avoided in pregnancy unless clearly necessary, although available evidence does not suggest a significant risk of harm to the developing baby. It is sometimes used short term for severe nausea and vomiting in pregnancy when first-line treatments such as cyclizine or promethazine have failed. Small amounts pass into breast milk, so it is usually avoided while breastfeeding. Any use in pregnancy or breastfeeding should be under direct clinical supervision.
If you forget a dose, take it as soon as you remember unless it is nearly time for the next dose — in which case skip the missed dose and continue with your normal schedule. Do not take a double dose to make up for the missed one, as this increases the risk of side effects including drowsiness and extrapyramidal reactions.
No — metoclopramide is not appropriate for long-term conditions such as gastroparesis, chronic reflux, or persistent functional nausea. The strict five-day limit applies to all UK indications. Patients with chronic upper gastrointestinal motility disorders should be assessed by a gastroenterologist for an appropriate long-term management plan that does not rely on metoclopramide.